QR Code

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression

Optimal treatment for metastatic non-small cell lung cancer (NSCLC) with mesenchymal epithelial transition gene (MET) exon 14 skipping mutation has not been established yet. MET inhibitors were demonstrated to be effective and tolerated in patients with this condition, while evidence on safety and e...

Full description

Saved in:
Main Authors: Alessandro Inno, Giuseppe Bogina, Giulio Settanni, Matteo Salgarello, Giovanni Foti, Carlo Pomari, Vincenzo Picece, Stefania Gori
Format: Artigo
Language:Inglês
Published: AboutScience Srl 2023-10-01
Series:Drug Target Insights
Subjects:
Elderly
First-line treatment
MET 14-exon skipping mutation
MET inhibitor
Non-small cell lung cancer
Tepotinib
Online Access:https://aboutscience.archicoop.it/index.php/dti/article/view/2626
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items